A Phase 3 interventional study of AZD9291 80 mg/40 mg and Placebo AZD9291 80 mg/40 mg in Stage IB-IIIA Non-small Cell Lung Carcinoma, sponsored by AstraZeneca. Active, not recruiting at 238 sites in 25 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.
Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 3rd largest by enrollment, is one of 5 that started in 2015, is one of 12 in phase 3, reaches primary completion later than 2 of the 42 other live ones, and was the 16th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:
Maastricht University Medical Center · Sites in Netherlands
Ages 18+
AstraZeneca · Sites in China
Ages 18+
Jonsson Comprehensive Cancer Center · Sites in United States
Ages 18+
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–99
Shanghai Chest Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, osimertinib is the treatment under test here. Read study by study →
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 52 · Phase 3 12 · Phase 4 4
First in 2013; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 682 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 51 across the 90 interventional studies. Of the 32 that completed or were terminated, 21 (66%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 90 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca: 25 open now, 78 under way, 28 of them phase 3. Of 123 finished, 45 (37%) have results posted.
Among the 209 studies in Carcinoma, Non-Small-Cell Lung by AstraZeneca, this one is the 20th largest by enrollment of the 137 interventional ones that give a count, is one of 14 that started in 2015, is one of 44 in phase 3, reaches primary completion later than 7 of the 77 other live ones, and was the 79th registered.
AstraZeneca’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
10 of the studies testing osimertinib in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05120349Phase 3AstraZenecaA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection | 2027-08-02 |
| NCT04285671Jonsson Comprehensive Cancer CenterNecitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer | 2026-12-02 |
| NCT04322890Hunan Province Tumor HospitalTreatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | 2026-12-24 |
| NCT07323641Jonsson Comprehensive Cancer CenterTelisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer | 2027-02-01 |
| NCT07485452Maastricht University Medical CenterBoosting Osimertinib Blood Brain Barrier Penetration | 2027-06 |
Add all 10 to your calendar (.ics) → With an account.
Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among AstraZeneca’s 209 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
To assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy
This is a phase 3 double-blind, randomized, placebo-controlled, study to assess the efficacy and safety of AZD9291 versus placebo in patients with stage IB-IIIA non-small cell lung cancer (NSCLC) with centrally confirmed, most common sensitising EGFR mutations (Ex19Del and L858R) either alone or in combination with other EGFR mutations as confirmed by a central test, who have had complete tumour resection, with or without postoperative adjuvant chemotherapy. Adjuvant chemotherapy should have consisted of a platinum based doublet given for a maximum of 4 cycles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment with any of the following:
Any of the following cardiac criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
Drug: AZD9291 80 mg/40 mg · Drug: Open-label AZD9291 80 mg/40 mg
Matching placebo for AZD9291 (80 mg or 40 mg orally, once daily), in accordance with the randomization schedule.
Drug: Placebo AZD9291 80 mg/40 mg
Drug page: Osimertinib
The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
Eligible patients will be offered open-label osimertinib upon recurrence and in the absence of intervening systemic anti-cancer therapy.
Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS).
Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).
Time frame: Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months)
Disease Free Survival (DFS) Rate at 2, 3 and 5 Years
Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.
Time frame: Up to approximately 5 years after the first patient is randomized (maximum follow up of 70 months). DFS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
Overall Survival (OS)
Defined as the time from the date of randomization until date of death due to any cause.
Time frame: Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months)
Overall Survival Rate at 2, 3 and 5 Years
Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.
Time frame: Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months). OS rate at 2 years (%), 3 years (%) and 5 years (%) are presented.
Patient Health-related Quality of Life and Symptoms (HRQoL) by SF-36v2 Health Survey.
Change from baseline will be calculated for each domain and summary scale at each scheduled post-baseline assessment. The SF-36 includes eight domains: Physical Functioning (PF); Role Limitations-Physical (RP), Vitality (VT), General Health Perceptions (GH), Bodily Pain (BP), Social Function (SF), Role Limitations-Emotional (RE), and Mental Health (MH) and two summary scores: The Physical Component Summary (PCS) and Mental Component Summary (MCS). Final scores for each scale range from 0-100 with higher scores indicating better health.
Time frame: Measured by SF-36 Questionnaire at baseline, 12 week, 24 week and then every 24 weeks until study complete, disease recurrence or other discontinuation criteria met, up to 3 years.
Plasma Concentrations of AZD9291
The pharmacokinetics exposure parameters derived from plasma concentrations of AZD9291
Time frame: Collected at pre-dose, 0.5-1.5hours and 2-4hours post-dose up to 96 weeks (approximately 24 months)
Plasma Concentrations of AZ5104 Metabolites
The pharmacokinetics exposure parameters derived from plasma concentrations of AZ5104 metabolites
Time frame: From date of dosing to week 96 (approximately 24 months)
Plasma Concentrations of AZ7550 Metabolites
The pharmacokinetics exposure parameters derived from plasma concentrations of AZ7550 metabolites
Time frame: From date of dosing to week 96 (approximately 24 months)
A total of 682 Patients were randomized to treatment at 245 Centers in 25 Countries.
| Milestone | AZD9291 | Placebo |
|---|---|---|
| Started | 339 | 343 |
| Received treatment | 337 | 343 |
| Completed | 261 | 234 |
| Not completed | 78 | 109 |
| Withdrew: Lost to follow-up | 6 | 4 |
| Withdrew: Withdrawal by subject | 24 | 21 |
| Withdrew: Death | 42 | 82 |
| Withdrew: Ongoing study at data cut-off | 3 | 2 |
| Withdrew: Without specified reason | 3 | 0 |
Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).
| Months | AZD9291 80mg Tablet | Placebo Tablet |
|---|---|---|
| Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS). | 65.8 (54.4 to NA) | 21.9 (16.6 to 27.5) |
Defined as the time from the date of randomization until the date of disease recurrence or death (by any cause in the absence of recurrence).
| Months | AZD9291 80mg Tablet | Placebo Tablet |
|---|---|---|
| Assess the Efficacy of AZD9291 Compared to Placebo as Measured by Disease Free Survival (DFS). | 65.8 (61.7 to NA) | 28.1 (22.1 to 35.0) |
Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.
| Percentage of participants | AZD9291 80mg Tablet | Placebo Tablet |
|---|---|---|
| DFS rate at 2 years (%) | 90.0 (85.2 to 93.3) | 46.1 (39.6 to 52.4) |
| DFS rate at 3 years (%) | 83.5 (77.8 to 87.8) | 33.8 (27.8 to 40.0) |
| DFS rate at 5 years (%) | 53.0 (43.0 to 62.1) | 24.9 (19.0 to 31.2) |
Defined as the percentage of patients alive and disease free at 2, 3 and 5 years, respectively, estimated from Kaplan Meier plots of the primary endpoint of DFS.
| Percentage of participants | AZD9291 80mg Tablet | Placebo Tablet |
|---|---|---|
| DFS rate at 2 years (%) | 90.1 (86.2 to 92.9) | 54.5 (49.0 to 59.7) |
| DFS rate at 3 years (%) | 84.5 (79.9 to 88.1) | 44.4 (39.0 to 49.7) |
| DFS rate at 5 years (%) | 60.9 (53.1 to 67.8) | 33.6 (28.0 to 39.2) |
Defined as the time from the date of randomization until date of death due to any cause.
| Months | AZD9291 80mg Tablet | Placebo Tablet |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Defined as the time from the date of randomization until date of death due to any cause.
| Months | AZD9291 80mg Tablet | Placebo Tablet |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.
| Percentage of participants | AZD9291 80mg Tablet | Placebo Tablet |
|---|---|---|
| OS rate at 2 years (%) | 99.5 (96.8 to 99.9) | 92.6 (88.3 to 95.3) |
| OS rate at 3 years (%) | 94.1 (90.1 to 96.5) | 85.9 (80.6 to 89.8) |
| OS rate at 5 years (%) | 85.0 (79.3 to 89.2) | 72.6 (66.0 to 78.1) |
Defined as the percentage of patients alive at 2, 3 and 5 years, respectively, estimated from a Kaplan Meier plot of OS.
| Percentage of participants | AZD9291 80mg Tablet | Placebo Tablet |
|---|---|---|
| OS rate at 2 years (%) | 99.4 (97.5 to 99.8) | 94.3 (91.2 to 96.3) |
| OS rate at 3 years (%) | 95.3 (92.3 to 97.1) | 88.8 (84.9 to 91.8) |
| OS rate at 5 years (%) | 87.6 (83.3 to 90.9) | 77.7 (72.7 to 81.9) |
Change from baseline will be calculated for each domain and summary scale at each scheduled post-baseline assessment. The SF-36 includes eight domains: Physical Functioning (PF); Role Limitations-Physical (RP), Vitality (VT), General Health Perceptions (GH), Bodily Pain (BP), Social Function (SF), Role Limitations-Emotional (RE), and Mental Health (MH) and two summary scores: The Physical Component Summary (PCS) and Mental Component Summary (MCS). Final scores for each scale range from 0-100 with higher scores indicating better health.
| Unit on a scale | AZD9291 80mg Tablet | Placebo Tablet |
|---|---|---|
| Week 12 - Bodily Pain | 1.026 ± 9.448 | 1.442 ± 8.854 |
| Week 24 - Bodily Pain | 1.521 ± 9.171 | 1.462 ± 9.279 |
| Week 48 - Bodily Pain | 2.032 ± 10.226 | 2.438 ± 10.077 |
| Week 72 - Bodily Pain | 2.471 ± 9.787 | 2.335 ± 9.566 |
| Week 96 - Bodily Pain | 2.326 ± 10.865 | 2.921 ± 10.153 |
| Week 120 - Bodily Pain | 2.906 ± 10.181 | 2.778 ± 11.295 |
| Week 144 - Bodily Pain | 3.045 ± 11.410 | 3.324 ± 10.258 |
| Week 156 - Bodily Pain | 2.552 ± 11.994 | 3.116 ± 10.692 |
| Week 12 - General Health Perceptions | -0.597 ± 8.319 | 0.343 ± 7.497 |
| Week 24 - General Health Perceptions | -0.079 ± 8.910 | 0.763 ± 8.122 |
| Week 48 - General Health Perceptions | 0.103 ± 8.029 | 1.042 ± 8.416 |
| Week 72 - General Health Perceptions | 0.275 ± 7.958 | 2.339 ± 8.197 |
| Week 96 - General Health Perceptions | -0.119 ± 8.195 | 1.818 ± 7.903 |
| Week 120 - General Health Perceptions | -0.368 ± 8.461 | 0.964 ± 8.518 |
| Week 144 - General Health Perceptions | 0.209 ± 8.671 | 1.342 ± 8.789 |
| Week 156 - General Health Perceptions | -0.128 ± 8.987 | 2.166 ± 8.670 |
| Week 12 - Mental Health | 0.928 ± 8.538 | 1.892 ± 8.497 |
| Week 24 - Mental Health | 1.249 ± 8.780 | 1.275 ± 9.660 |
| Week 48 - Mental Health | 2.456 ± 8.920 | 2.234 ± 8.676 |
| Week 72 - Mental Health | 1.540 ± 9.029 | 2.011 ± 8.954 |
| Week 96 - Mental Health | 1.352 ± 8.560 | 2.101 ± 8.986 |
| Week 120 - Mental Health | 0.723 ± 9.738 | 2.307 ± 10.139 |
| Week 144 - Mental Health | 0.517 ± 9.609 | 1.428 ± 8.914 |
| Week 156 - Mental Health | 0.386 ± 10.215 | 2.000 ± 9.651 |
| Week 12 - Physical functioning | -0.314 ± 6.762 | 0.898 ± 6.646 |
| Week 24 - Physical functioning | 0.494 ± 6.783 | 0.923 ± 7.014 |
| Week 48 - Physical functioning | 0.940 ± 7.595 | 1.914 ± 7.899 |
| Week 72 - Physical functioning | 1.079 ± 6.725 | 2.042 ± 7.283 |
| Week 96 - Physical functioning | 0.637 ± 8.220 | 2.016 ± 7.048 |
| Week 120 - Physical functioning | 1.449 ± 7.207 | 2.540 ± 7.424 |
| Week 144 - Physical functioning | 1.869 ± 6.767 | 1.939 ± 8.238 |
| Week 156 - Physical functioning | 0.997 ± 7.537 | 2.187 ± 8.293 |
| Week 12 - Role Limitations - Emotional | 0.381 ± 10.413 | 2.333 ± 11.168 |
| Week 24 - Role Limitations - Emotional | 0.858 ± 11.317 | 1.678 ± 11.571 |
| Week 48 - Role Limitations - Emotional | 2.179 ± 11.131 | 2.628 ± 10.952 |
| Week 72 - Role Limitations - Emotional | 1.410 ± 11.861 | 1.860 ± 11.424 |
| Week 96 - Role Limitations - Emotional | 1.657 ± 12.405 | 1.899 ± 12.379 |
| Week 120 - Role Limitations - Emotional | 1.765 ± 11.966 | 2.360 ± 12.663 |
| Week 144 - Role Limitations - Emotional | 1.654 ± 12.081 | 2.532 ± 13.113 |
| Week 156 - Role Limitations - Emotional | 0.519 ± 12.351 | 2.201 ± 13.022 |
| Week 12 - Role Limitations - Physical | 1.056 ± 9.263 | 2.915 ± 8.977 |
| Week 24 - Role Limitations - Physical | 1.727 ± 10.265 | 4.063 ± 9.295 |
| Week 48 - Role Limitations - Physical | 3.437 ± 10.592 | 5.332 ± 9.663 |
| Week 72 - Role Limitations - Physical | 3.581 ± 11.037 | 5.424 ± 9.670 |
| Week 96 - Role Limitations - Physical | 3.240 ± 10.807 | 5.321 ± 9.997 |
| Week 120 - Role Limitations - Physical | 4.717 ± 11.238 | 5.348 ± 11.395 |
| Week 144 - Role Limitations - Physical | 3.525 ± 10.860 | 5.444 ± 10.547 |
| Week 156 - Role Limitations - Physical | 3.151 ± 11.378 | 5.572 ± 10.954 |
| Week 12 - Social Function | 1.391 ± 9.615 | 3.164 ± 9.171 |
| Week 24 - Social Function | 2.634 ± 9.526 | 3.433 ± 10.348 |
| Week 48 - Social Function | 3.731 ± 9.919 | 4.170 ± 10.156 |
| Week 72 - Social Function | 3.025 ± 10.094 | 4.802 ± 10.351 |
| Week 96 - Social Function | 3.651 ± 10.011 | 4.405 ± 10.790 |
| Week 120 - Social Function | 3.297 ± 10.723 | 4.386 ± 11.355 |
| Week 144 - Social Function | 2.582 ± 10.638 | 3.912 ± 10.929 |
| Week 156 - Social Function | 2.423 ± 10.658 | 4.351 ± 12.144 |
| Week 12 - Vitality | 0.570 ± 7.987 | 2.344 ± 8.207 |
| Week 24 - Vitality | 0.630 ± 8.996 | 2.463 ± 9.461 |
| Week 48 - Vitality | 2.231 ± 9.209 | 3.029 ± 8.972 |
| Week 72 - Vitality | 1.082 ± 9.387 | 3.815 ± 8.869 |
| Week 96 - Vitality | 1.147 ± 9.052 | 3.474 ± 9.071 |
| Week 120 - Vitality | 1.139 ± 9.458 | 3.224 ± 9.122 |
| Week 144 - Vitality | 0.386 ± 9.724 | 2.070 ± 9.285 |
| Week 156 - Vitality | 0.825 ± 9.342 | 2.970 ± 8.831 |
| Week 12 - Mental Component Summary | 0.986 ± 8.068 | 2.603 ± 8.965 |
| Week 24 - Mental Component Summary | 1.333 ± 8.919 | 1.936 ± 10.152 |
| Week 48 - Mental Component Summary | 2.788 ± 9.301 | 2.757 ± 9.141 |
| Week 72 - Mental Component Summary | 1.434 ± 9.635 | 2.577 ± 9.116 |
| Week 96 - Mental Component Summary | 1.823 ± 9.439 | 2.415 ± 10.023 |
| Week 120 - Mental Component Summary | 1.027 ± 10.286 | 2.554 ± 10.548 |
| Week 144 - Mental Component Summary | 0.580 ± 9.994 | 1.870 ± 9.857 |
| Week 156 - Mental Component Summary | 0.322 ± 10.077 | 2.269 ± 10.647 |
| Week 12 - Physical Component Summary | 0.161 ± 6.341 | 1.144 ± 6.078 |
| Week 24 - Physical Component Summary | 0.878 ± 7.009 | 1.938 ± 6.643 |
| Week 48 - Physical Component Summary | 1.356 ± 6.800 | 2.797 ± 7.497 |
| Week 72 - Physical Component Summary | 1.989 ± 6.941 | 3.360 ± 6.985 |
| Week 96 - Physical Component Summary | 1.497 ± 7.591 | 3.343 ± 6.792 |
| Week 120 - Physical Component Summary | 2.611 ± 7.291 | 3.175 ± 8.210 |
| Week 144 - Physical Component Summary | 2.635 ± 7.374 | 3.353 ± 8.042 |
| Week 156 - Physical Component Summary | 2.133 ± 7.909 | 3.644 ± 8.731 |
The pharmacokinetics exposure parameters derived from plasma concentrations of AZD9291
| nM | AZD9291 80mg Tablet |
|---|---|
| Week 4 - Pre-dose | 380.2563 ± 60.4465 |
| Week 4 - 0.5-1.5 hours | 383.9142 ± 74.3191 |
| Week 4 - 2-4 hours | 463.0098 ± 56.3562 |
| Week 24- Pre-dose | 288.8266 ± 181.8255 |
| Week 24 - 0.5-1.5 hours | 303.8269 ± 116.9411 |
| Week 24 - 2-4 hours | 358.831 ± 116.0567 |
| Week 48- Pre-dose | 301.7346 ± 125.4901 |
| Week 48 - 0.5-1.5 hours | 311.3503 ± 101.1574 |
| Week 48 - 2-4 hours | 375.6666 ± 69.9838 |
| Week 96- Pre-dose | 287.5375 ± 95.6634 |
| Week 96 - 0.5-1.5 hours | 273.3198 ± 126.003 |
| Week 96 - 2-4 hours | 341.5805 ± 79.0578 |
The pharmacokinetics exposure parameters derived from plasma concentrations of AZ5104 metabolites
| nM | AZ5104 |
|---|---|
| Week 4 - Pre-dose | 44.4619 ± 66.2108 |
| Week 4 - 0.5-1.5 hours | 45.2280 ± 67.0500 |
| Week 4 - 2-4 hours | 49.6081 ± 65.5757 |
| Week 24 - Pre-dose | 38.7314 ± 111.0996 |
| Week 24 - 0.5-1.5 hours | 39.1687 ± 86.1118 |
| Week 24 - 2-4 hours | 41.3251 ± 99.2633 |
| Week 48 - Pre-dose | 41.1778 ± 53.8923 |
| Week 48 - 0.5-1.5 hours | 40.9276 ± 53.9916 |
| Week 48 - 2-4 hours | 42.9143 ± 68.8102 |
| Week 96 - Pre-dose | 38.0205 ± 81.4442 |
| Week 96 - 0.5-1.5 hours | 36.9723 ± 101.2317 |
| Week 96 - 2-4 hours | 39.8057 ± 78.0300 |
The pharmacokinetics exposure parameters derived from plasma concentrations of AZ7550 metabolites
| nM | AZ7550 |
|---|---|
| Week 4 - Pre-dose | 44.3492 ± 56.5153 |
| Week 4 - 0.5-1.5 hours | 44.7386 ± 55.0410 |
| Week 4 - 2-4 hours | 48.0864 ± 61.8700 |
| Week 24 - Pre-dose | 40.7113 ± 75.3663 |
| Week 24 - 0.5-1.5 hours | 40.9375 ± 65.8656 |
| Week 24 - 2-4 hours | 44.1476 ± 60.2684 |
| Week 48 - Pre-dose | 41.3862 ± 52.2259 |
| Week 48 - 0.5-1.5 hours | 41.0467 ± 52.9773 |
| Week 48 - 2-4 hours | 40.4486 ± 99.6574 |
| Week 96 - Pre-dose | 28.1890 ± 180.0937 |
| Week 96 - 0.5-1.5 hours | 30.2419 ± 155.4156 |
| Week 96 - 2-4 hours | 33.9653 ± 79.2841 |
Collected over Adverse events with onset date on or after the date of first dose up to and including 28 days following discontinuation of study treatment and before starting subsequent cancer therapy, up to approximately 3 years. All-Cause Mortality assessed up to approximately 7 years.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AZD9291 | 42/339 (12.4%) | 68/337 (20.2%) | 312/337 (92.6%) |
| Placebo | 82/343 (23.9%) | 47/343 (13.7%) | 262/343 (76.4%) |
| Event | AZD9291 | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 5/337 | 4/343 |
| Acute kidney injuryRenal and urinary disorders | 2/337 | 0/343 |
| UreterolithiasisRenal and urinary disorders | 2/337 | 0/343 |
| CataractEye disorders | 2/337 | 0/343 |
| DiarrhoeaGastrointestinal disorders | 2/337 | 0/343 |
| Large intestine polypGastrointestinal disorders | 2/337 | 0/343 |
| InfluenzaInfections and infestations | 2/337 | 0/343 |
| Femur fractureInjury, poisoning and procedural complications | 2/337 | 1/343 |
| HyperuricaemiaMetabolism and nutrition disorders | 2/337 | 1/343 |
| Coronary artery diseaseCardiac disorders | 1/337 | 1/343 |
| Event | AZD9291 | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 158/337 | 71/343 |
| ParonychiaInfections and infestations | 92/337 | 5/343 |
| Dry skinSkin and subcutaneous tissue disorders | 84/337 | 23/343 |
| PruritusSkin and subcutaneous tissue disorders | 70/337 | 30/343 |
| CoughRespiratory, thoracic and mediastinal disorders | 66/337 | 61/343 |
| StomatitisGastrointestinal disorders | 59/337 | 15/343 |
| Upper respiratory tract infectionInfections and infestations | 53/337 | 38/343 |
| NasopharyngitisInfections and infestations | 50/337 | 36/343 |
| Decreased appetiteMetabolism and nutrition disorders | 49/337 | 12/343 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 41/337 | 16/343 |
| Age, Continuous(Years) | AZD9291 | Placebo | Total |
|---|---|---|---|
| Mean | 62.5 ± 10.3 | 61.6 ± 10.5 | 62.1 ± 10.4 |
| Sex: Female, Male(Participants) | AZD9291 | Placebo | Total |
|---|---|---|---|
| Female | 230 | 248 | 478 |
| Male | 109 | 95 | 204 |
| Race/Ethnicity, Customized(Participants) | AZD9291 | Placebo | Total |
|---|---|---|---|
| ASIAN (OTHER THAN CHINESE AND JAPANESE) | 77 | 65 | 142 |
| CHINESE | 95 | 100 | 195 |
| HISPANIC OR LATINO | 12 | 9 | 21 |
| JAPANESE | 47 | 53 | 100 |
| OTHER | 108 | 116 | 224 |
| Race/Ethnicity, Customized(Participants) | AZD9291 | Placebo | Total |
|---|---|---|---|
| AMERICAN INDIAN OR ALASKA NATIVE | 0 | 0 | 0 |
| ASIAN | 216 | 218 | 434 |
| BLACK OR AFRICAN AMERICAN | 0 | 0 | 0 |
| UNKNOWN OR NOT REPORTED | 0 | 1 | 1 |
| NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER | 0 | 0 | 0 |
| OTHER | 1 | 2 | 3 |
| WHITE | 122 | 122 | 244 |
| Region of Enrollment(Participants) | AZD9291 | Placebo | Total |
|---|---|---|---|
| Australia | 7 | 9 | 16 |
| Belgium | 0 | 1 | 1 |
| Brazil | 8 | 6 | 14 |
| Canada | 1 | 3 | 4 |
| China | 77 | 82 | 159 |
| Germany | 7 | 5 | 12 |
| Spain | 14 | 16 | 30 |
| France | 4 | 5 | 9 |
| Hong Kong, S.A.R., China | 4 | 4 | 8 |
| Hungary | 1 | 1 | 2 |
| Israel | 9 | 3 | 12 |
| Italy | 15 | 17 | 32 |
| Japan | 46 | 53 | 99 |
| Poland | 4 | 9 | 13 |
| Romania | 2 | 2 | 4 |
| Russia | 43 | 39 | 82 |
| Sweden | 1 | 1 | 2 |
| Thailand | 16 | 17 | 33 |
| Turkey | 3 | 8 | 11 |
| Taiwan, China | 24 | 22 | 46 |
| Ukraine | 2 | 1 | 3 |
| United States | 13 | 8 | 21 |
| Viet Nam | 11 | 13 | 24 |
| Korea, Republic Of | 27 | 18 | 45 |
Showing the first 100 of 238 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Oct 2015 to primary completion in Apr 2022, 77 months.
Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's 77 months is above that.
Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Osimertinib
Carcinoma, Non-Small-Cell Lung →